Texture Features and PDL1 in CT-PET 18 FDG

March 16, 2020 updated by: University Hospital, Montpellier

Correlation Between Texture Features With CT-PET 18 FDG and Overexpression of PDL1 in Non-small-cell Lung Carcinomas During the Initial Staging.

Search correlation between texture features in CT-PET 18 FDG and overexpression of PDL1 in non-small cell lung carcinomas during the inital staging.

The hypothesis is that overexpression of PDL1is correlated with at least one texture feature among those selected.

84 CT-PET 18 FDG at the initial staging of a non small cell lung carcinoma (adenocarcinoma or squamous cell carcinoma), whose the biopsed site was the primitive site or the drainage lymphadenopathy, without previous treatment, were recruited and analyzed by a software allowing to estimate texture features.

Study Overview

Status

Completed

Conditions

Non Small Cell Lung Cancer

Study Type

Observational

Enrollment (Actual)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

France
- - Montpellier, France, 34295
    - Uh Montpellier

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult patient with initial CT-PET 18 FDG realized in the nuclear service of Montpellier university hospital, with non small cell lung carcinoma diagnosed with biopsy of the primitive site or local drainage lymphadenopathy.

Description

Inclusion criteria:

adult patient ;
first CT-PET 18 FDG realized for the inital staging ;
absence of previous treatment for a thoracic neoplasm ;
biopsy realized on the primitive site or local drainage lymphadenopathy ;
primitive site viewable with morphological imagery ;
availability of evaluation of PDL1's overexpression ;

Exclusion criteria

- Refusal to participate in this research

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort
Overexpression of PDL1
Absence of overexpression of PDL1

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation between at least one texture feature and overexpression of PDL1 Time Frame: 1 day	Correlation between at least one texture feature and overexpression of PDL1	1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Montpellier

Investigators

Principal Investigator: Jean-Baptiste MALLET, University Hospitals of Montpellier

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2018

Primary Completion (Actual)

October 1, 2018

Study Completion (Actual)

January 31, 2020

Study Registration Dates

First Submitted

March 12, 2020

First Submitted That Met QC Criteria

March 12, 2020

First Posted (Actual)

March 16, 2020

Study Record Updates

Last Update Posted (Actual)

March 18, 2020

Last Update Submitted That Met QC Criteria